Outsourced Pharma Capacity Update – Antibody-Drug Conjugate

Discover the crucial role CDMOs play in the development and manufacturing of Antibody-Drug Conjugates (ADCs). These groundbreaking therapies, combining monoclonal antibodies with cancer cell-targeting payloads, offer precise targeting and powerful anticancer effects. Learn how to collaborate with CDMO partners and stay at the forefront of oncology advancements.

What can you expect? – Short, digestible presentations with live interaction to give you an inside look at the available capacity of industry suppliers. You will have the opportunity to ask questions of each CDMO to better understand if they can meet your needs – all from the convenience of your computer!

Please note that this event is for biopharma companies seeking available capacity to connect with CDMOs who have that capacity available.

Attendance is open to the following:
Individuals working for a pharma or biotech company with an active therapeutic pipeline
Industry consultants and capital investment firms
CDMO sponsors of the event